Innoviva (INVA) EBT Margin (2011 - 2026)
Innoviva's (INVA) quarterly EBT Margin came in at 239.36% in Q1 2026, up 28290.0% YoY from N/an in Q1 2025, and up 115.19% on a QoQ basis from 1575.3% in Q4 2025.
Powered by 
Analysis
Innoviva (INVA) EBT Margin (2011 - 2026) Analysis & Trends
Innoviva (INVA) has 16 years of EBT Margin data on file, last reported at 239.36% in Q1 2026.
- Quarterly EBT Margin rose 28290.0% year-over-year to 239.36% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 85.05% (up 14271.0% YoY) and the FY2025 annual result came in at 79.47%, up 7946.0% from the prior year.
- EBT Margin rose to 239.36% in Q1 2026, from 1575.3% in the prior quarter.
- In the past five years, EBT Margin ranged from a high of 2227.4% in Q1 2023 to a low of 16046.48% in Q4 2024.
- A 5-year average of 740.03% and a median of 59.16% in 2023 frame the typical range for EBT Margin.
- Annual changes were most pronounced in 2024 — EBT Margin plunged 1538038 bps — and 2025, when it soared 1447118 bps.
- Tracing INVA's EBT Margin over 5 years: stood at 1513.13% in 2022, then jumped by 56 bps to 666.1% in 2023, then plunged by 2309 bps to 16046.48% in 2024, then soared by 90 bps to 1575.3% in 2025, then surged by 115 bps to 239.36% in 2026.
- The last three EBT Margin figures came in at 239.36% (Q1 2026), 1575.3% (Q4 2025), and 44.43% (Q3 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 41.75% |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 35.61% |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | 35.78% |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | -528.97% |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 18.33% |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 13.77% |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 12.09% |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | -2.67% |
| 10 | Innoviva | 1.56 Bn | 984.81 Mn | 90.62 Mn | -90.32% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -90.32% |
| Mar 31, 2026 | 239.36% |
| Dec 31, 2025 | -1,274.01% |
| Sep 30, 2025 | 44.43% |
| Jun 30, 2025 | 72.39% |
| Mar 31, 2025 | -43.54% |
| Dec 31, 2024 | -853.36% |
| Sep 30, 2024 | 4.76% |
| Jun 30, 2024 | -39.32% |
| Mar 31, 2024 | 58.23% |
| Dec 31, 2023 | -430.50% |
| Sep 30, 2023 | 59.16% |
| Jun 30, 2023 | 7.17% |
| Mar 31, 2023 | 53.87% |
| Dec 31, 2022 | -982.68% |
| Sep 30, 2022 | 132.43% |
| Jun 30, 2022 | 18.94% |
| Mar 31, 2022 | 49.65% |
| Dec 31, 2021 | -611.53% |
| Sep 30, 2021 | 136.81% |